Strategy
MSTR
MARA Holdings
MARA
NVIDIA
NVDA
Tesla
TSLA
Coinbase
COIN
US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 0.8400
- +0.0438+5.50%
Close Feb 28 16:00 ET
- 0.9100
- +0.0700+8.33%
Post 20:01 ET
154.94MMarket Cap-1.00P/E (TTM)
0.8500High0.7801Low1.16MVolume0.7874Open0.7962Pre Close966.68KTurnover0.68%Turnover RatioLossP/E (Static)184.46MShares1.928052wk High3.17P/B144.59MFloat Cap0.650052wk Low--Dividend TTM172.13MShs Float111.3600Historical High--Div YieldTTM8.78%Amplitude0.4126Historical Low0.8300Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Nektar Therapeutics Stock Forum
Can Nektar's T-cell Therapy Revolutionize Alopecia Treatment? Phase 2b Trial Fully Enrolled
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Wednesday, 26th February at 7:00 am
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
Re...
This Phase 2 trial announcement represents a strategic advancement in Nektar's development of rezpegaldesleukin for type 1 diabetes treatment. The collaboration with TrialNet, a leading international diabetes research network, significantly enhances the trial's credibility and execution potential. The study's design is particularly robust, incorporating both mixed meal tolerance testing and C-peptide preservation measurements - important ma...
Can This New Diabetes Treatment Change T1D Patient Care? Major Trial Announced
$Nektar Therapeutics (NKTR.US)$
taking a position here
The FDA's Fast Track designation for rezpegaldesleukin marks a important inflection point for Nektar Therapeutics in the $14 billion global atopic dermatitis market. The designation's significance extends beyond mere regulatory acceleration - it validates the drug's novel approach in a highly competitive landscape dominated by JAK inhibitors and biologics like Dupixent.
The drug's mechanism of action targeting regulatory T c...
Nektar's Breakthrough: FDA Accelerates Path for Revolutionary Skin Disease Treatment
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
No comment yet